United States Daily Briefing

Johnson & Johnson fell $15.12 to $248.61 in Tuesday's session, the worst performance among the S&P 500 losers. The magnitude of the move — nearly 6% in a single session — implies a litigation verdict, earnings miss, or guidance cut of material significance. ABBV compounded the healthcare damage, shedding 2.40% to $274.36. Combined, the pharma pair stripped roughly 50 basis points from any healthcare-tilted portfolio today, and the sector ETF XLV finished -1.35%.

JPMorgan Chase reported its first fixed-income, currencies, and commodities revenue decline in over two years — $5.37 billion in Q3, missing analyst consensus. Equity trading at $4.95 billion partially offset the shortfall, but the FICC weakness is a structural signal: the extreme rate-volatility environment that powered bank trading revenues through 2022-2024 is normalising. JPM stock fell 0.86% to $331.43 and finished among the session's losers.

While AI mega-caps faced a mixed session per Asian briefings' read of NY markets, Tuesday's US tape showed selective AI strength: ORCL +4.23% to $143.20 (likely on enterprise AI contract flow), META +2.63% to $762.50, and AMD +1.90% to $605.53. The Comm Services sector +0.74% reflected the META lift. This divergence — AI software/infra winning while hardware wobbles — is the dominant intra-sector rotation theme heading into Alphabet and Meta earnings this week.